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ORIGINAL ARTICLE

Effect of Low Body Mass Index in Outcome of Micra
Leadless Pacemaker Implantation
Mark Tsz-Kin Tam*, Anna Kin-Yin Chan, Alex Chi-Kin Au, Lily Cheung,
Gary Chin-Pang Chan, Joseph Yat-Sun Chan
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

Abstract
Background: Implantation of Micra transcatheter pacing system (TPS) requires introduction of a large caliber delivery
catheter into patient's venous system and right heart. While the investigational device exemption study population had a
mean body mass index (BMI) of 27.6kg/m2, implantation outcome in patients with small body size requires further
investigation. This study sought to evaluate the effect of low BMI in outcome of Micra TPS implantation
Method: Consecutive patients undergoing Micra TPS implantation between 19 September 2015 and 24 May 2018 in a
single tertiary referral center were studied. Procedure efﬁcacy outcome was deﬁned as successful implantation with
threshold being low (≤2.0V/0.24msec) and stable (increase in threshold of ≤1.5V/0.24 msec) at implantation and clinical
follow-up in the ﬁrst year. Procedure safety outcome was deﬁned as absence of major complications in the ﬁrst year after
implantation. A primary analysis was planned to identify factors affecting the composite procedure efﬁcacy and safety
outcome, with the hypothesis that low BMI would be associated with poor composite outcome. A secondary analysis was
planned to study the effect of BMI on ﬁnal implant position, number of device deployment and procedure time.
Results: 147 patients were included in the study. The mean BMI of the cohort was signiﬁcantly lower than that in the
investigational device exemption study (23.7 ± 3.7kg/m2 vs 27.6 ± 5.3 kg/m2, p < 0.0001). Composite procedure safety and
efﬁcacy outcome was reached in 136 patients (92.5%). Low BMI and low body weight were both associated with poor
composite procedure and safety outcome (p ¼ 0.001 and p ¼ 0.007, respectively). After dividing the included patients
into low BMI and higher BMI groups using median BMI of 23.76kg/m2 as cut off, low BMI group was more likely to
result in mid or high septal deployment (51% vs 17%, p < 0.001), required more deployment attempts (1.86 ± 1.97 vs
1.27 ± 0.97, p ¼ 0.026), more likely to require recapture of device (31% vs 17%, p ¼ 0.049) and had a longer procedure
time (46.0 ± 20.5 minutes vs 37.7 ± 15.4 minutes, p ¼ 0.007).
Conclusion: Micra leadless pacemaker implantation in patients with low BMI was associated with an unfavorable
composite efﬁcacy and safety outcomes. Implantation in patients with low BMI was associated with a higher right
ventricular implantation position, requiring more deployment attempts and longer procedure time. More data is needed
to determine the optimal pacing approach for this high-risk group of patients.
Keywords: Leadless pacemaker, Implantation, Device therapy, Bradycardia

Introduction

T

ransvenous pacemaker implantation is an
established conventional treatment for bradyarrhythmia [1,2]. However, it carries risks
including pocket and lead related complications

[3e8]. Leadless pacemaker is an effective alternative
in selected patients [9e11]. There are two leadless
pacing systems available in the market - Micra
transcatheter pacing system (Micra TPS, Medtronic,
Minneapolis, MN, USA) [11] and Nanostim leadless
pacemaker (Nanostim LP, Abbott Medical, Sylmar,
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CA, USA) [9]. The former was approved by the
United States and European regulatory bodies and
is available for commercial use worldwide.
In the Investigational Device Exemption (IDE)
study, Micra TPS was found to maintain stable and
electrical parameters in early post-implantation
follow-up [11]. Post hoc analysis also showed lower
complication rate when compared with a matched
historical cohort with transvenous pacemakers [11].
Subsequent post-approval registry (PAR) also yielded similar promising results in a longer-term
follow-up [12e14].
However, in the IDE study, the mean body mass
index was 27.6kg/m2, suggesting a population with
relatively large body habitus [11]. Subsequent postapproval registry (PAR) did not report patients'
body mass index (BMI) [13,14]. Implantation of
Micra TPS is performed with a large-caliber delivery
catheter (23 French) and delivery sheath (27 French
outer diameter) [15]. Concern has been raised when
introducing the delivery catheter into patient's
venous system and negotiating inside the right
heart, especially in patients with small body build
[16]. Directing the large caliber delivery catheter to
the desired implant position may also be more
difﬁcult in small right ventricles (RV) [16]. Thus,
implantation in patients with small body habitus
demands extra caution to avoid vascular injury and
cardiac perforation. Previous studies did ﬁnd low
BMI to be associated with cardiac injury [17].
However, aside from this, little is known on how
small body build would affect the implant efﬁcacy
and safety.
Asian patients are of relatively smaller body build
compared with Western population [18] and hence
may be at higher risk. However, Asians comprise
only 1.7% of the study population of IDE trial [11]. A
study of Micra TPS implantation in this population
is anticipated to verify its safety and efﬁcacy in patients with small body build.

Methods
Study design and data collection
This was a retrospective study of Micra TPS
implantation in Prince of Wales Hospital, which is
a tertiary referral hospital in Hong Kong, afﬁliated
to Chinese University of Hong Kong (CUHK).
Consecutive patients undergoing implantation of
Micra TPS at the institution for the treatment of
bradyarrhythmias in the period between 19
September 2015 and 24 May 2018 were analyzed.
The electronic patients record (EPR) system and
clinical written notes of all enrolled patients were

reviewed to obtain necessary information. Patients’ demographics, electrocardiogram (ECG),
echocardiographic data and comorbidities were
gathered. All procedure records were reviewed to
determine procedure time. Each patient's implantation ﬂuoroscopic images were reviewed by an
interpreter blinded from patients' clinical details to
determine the number of device deployment attempts. The blinded interpreter also judged the
ﬁnal implantation position, which was categorized
as high if device was at mid or high septal position, or low if device was at apex or low septum.
The device electrical parameters including sensing
amplitude, pacing threshold and impedance were
also recorded during implantation and follow-up
visits.
Deﬁnitions and calculations
Body mass index (BMI) was calculated with the
following formula
BMI (in kg/m2) ¼ body weight in kg/(body height in
m)2
Body surface area (BSA) was estimated with the
Mosteller formula [19].
BSA (in m2) ¼ (body weight in kg)0.5  (body height
in cm)0.5  0.16667
Renal dysfunction was deﬁned as an estimated
glomerular ﬁltration rate of less than 60mL/min/
1.73 m2 [2]. Consistent with existing guideline, the
estimated glomerular ﬁltration rate (eGFR) was
calculated by the CKD-EPI formula for non-black
population as follows [20].
eGFR ¼ 141  min(SCr/k, 1)a  max(SCr/k, 1)1.209 
0.993Age  1.018 [if female]
where SCr ¼ serum creatinine in mg/dL, k ¼ 0.7
(females) or 0.9 (males), a ¼ 0.329 (females) or
0.411 (males), min indicates the minimum of SCr/k
or 1, max indicates the maximum of SCr/k or 1
Implantation procedure
The implantation procedure for Micra TPS was
described by the manufacturer's protocol [21]. In
brief, access at right femoral vein was followed by
serial dilatation of wound to accommodate the 27
French Micra delivery sheath. A bolus of heparin
was given intravenously adjusted to patient's body
weight, unless patient had been systemically anticoagulated by warfarin or non-vitamin K oral
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anticoagulants. The delivery catheter was introduced into the RV by carefully ﬂexing it. Its position inside RV was checked by contrast injection at
right anterior oblique (RAO) and left anterior
oblique (LAO) views. A clockwise torque was
maintained to ensure the device was pointing towards the RV septum in LAO view. With satisfactory positioning, a gentle forward push of the
delivery catheter was made to ensured optimal
device contact with the ventricular trabeculae. After
that, the device was released. Security of device
ﬁxation was veriﬁed by pull and hold test, then
electrical parameters were evaluated. If electrical
parameters were suboptimal, recapture of device
would be performed. With ﬁxation veriﬁed and
satisfactory parameters obtained, the tether that
connects the device with the delivery catheter
would be cut and the delivery system would be
removed. Wound closure would be made by skin
suturing and manual compression.
Implantation position
Device location was determined according to position in RAO and LAO projections. With RAO
image, the height of implant position was classiﬁed
into high, mid, low or apical. With LAO image, the
device's septal orientation was adjudicated.

Study outcomes and analysis
Procedure efﬁcacy outcome was deﬁned as successful implantation with threshold being low
(2.0V at a pulse width of 0.24 msec at implant and
follow up) and stable (increase in threshold of 1.5V
at a pulse width of 0.24 msec comparing with implantation threshold) at implantation and all clinical
follow up in the ﬁrst year. Procedure safety outcome
was deﬁned as absence of major complications
including events resulting in death, permanent loss
of device function as a result of mechanical or
electrical dysfunction, hospitalization, prolongation
of hospitalization by at least 48 hours, or system
revision.
A primary analysis was planned to identify predictors for the composite procedure efﬁcacy and
safety outcome, with the hypothesis that smaller
body habitus was associated with poor composite
efﬁcacy and safety outcome. A secondary analysis
was planned to study the effect of patients’ BMI on
ﬁnal implant position, number of device deployment and procedure time.
Statistical analysis
Categorical variables were presented in frequency
tables and were compared using the Pearson's Chi

Table 1. Baseline characteristics and comparison with IDE study and PAR.
Age (year)
Male
BMI (kg/m2)
BSA (m2)
LVEF (%, n¼83 available)
Hypertension
Atrial arrhythmia
Diabetes
Renal dysfunction
Dialysis
Previously implanted CIED
CIED infection
Coronary artery disease
COPD
CHF
Pacing indication
Brady with AF
SSS
AV block
Syncope
Other
Not reported

IDE (n ¼ 725)

PAR (n ¼ 1817)

CUHK (n ¼ 147)

P valuea

P valueb

75.9 ± 10.9
426 (58.8)
27.6 ± 5.3
NA
58.9 ± 8.8
570 (78.6%)
548 (75.5%)
207 (28.6%)
145 (20.0%)
NA
0
0
203 (28%)
90 (12.4%)
123 (17%)

75.6 ± 13.5
1111 (61.1%)
NA
NA
NA
1165 (64.1%)
1370 (75.4%)
480 (26.4%)
NA
NA
265 (14.6%)
NA
402 (22.1%)
176 (9.7%)
234 (12.9%)

80.5 ± 8.7
73 (49.7%)
23.7 ± 3.7
1.60 ± 0.18
57.9 ± 7.9
100 (68%)
83 (56.5%)
47 (32%)
80 (54.4%)
6 (4.1%)
14 (9.5%)
8 (5.4%)
23 (15.6%)
3 (2.0%)
31 (21.1%)

p < 0.0001
0.042
p < 0.0001
NA
p ¼ 0.3222
0.0055
<0.0001
0.41
p < 0.0001
NA
<0.0001
<0.0001
p ¼ 0.0018
p < 0.0001
0.23
p ¼ 0.0015

p < 0.0001
0.0081
NA
NA
NA
0.34
<0.0001
0.14
NA
NA
0.091
NA
0.067
p ¼ 0.0008
0.0051
<0.0001

464 (63.9%)
126 (17.4%)
109 (15%)
16 (2.2%)
11 (1.5%)
0

1127 (62.0%)
177 (9.7%)
211 (11.6%)
243 (13.4%)
50 (2.8%)
9 (0.5%)

83 (56.5%)
23 (15.6%)
39 (26.5%)
0
1 (0.7%)
1 (0.7%)

BMI ¼ body mass index; BSA ¼ body surface area; LVEF ¼ left ventricular ejection fraction; CIED ¼ cardiovascular implantable
electronic device; COPD ¼ chronic obstructive pulmonary disease; CHF ¼ congestive heart failure; AF ¼ atrial ﬁbrillation; SSS ¼ sick
sinus syndrome; AV ¼ atrioventricular; IDE¼Investigational Device Exemption; PAR¼post-approval registry.
a
P value of comparisons between IDE and CUHK cohort.
b
P value of comparisons between PAR and CUHK cohort.
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square test if all cell sizes were more than 5, or
Fisher’s exact test if otherwise. Parametric and
nonparametric continuous variables were expressed
as mean ± SD and median (interquartile range) and
were compared using the Student t-test and
ManneWhitney U test, respectively. P < 0.05 was
considered statistically signiﬁcant. All statistical
analyses were performed using SPSS version 24.0.

Results
Patient characteristics
Between 19 September 2015 and 24 May 2018, a
total of 147 Micra TPS implantation procedures
were performed (Table 1). The mean age of the
cohort was 80.5 ± 8.7 years, which was higher than
that in both the IDE trial and registry population.
Half of the cohort was male (n ¼ 73, 49.7%), which
was less than that of IDE and PAR. Our cohort had
different comorbidity proﬁle with a higher incidence of renal dysfunction (n ¼ 80, 54.4%) and
congestive heart failure (n ¼ 31, 21.1%) but lower
incidence of hypertension (n ¼ 100, 68%), atrial
arrhythmia (n ¼ 83, 56.5%), coronary artery disease
(n ¼ 23, 15.6%) and chronic obstructive pulmonary
disease (COPD) (n ¼ 3, 2.0%). Unlike IDE, which
excluded patients with prior implanted transvenous
pacemakers or history of device related infection,
our cohort included those patients (n ¼ 14, 9.5%;
and n ¼ 8, 5.4% respectively). The most common
indication for pacing was bradyarrhythmia with
atrial ﬁbrillation (AF) (n ¼ 83, 56.5%), followed by
atrioventricular (AV) block (n ¼ 39, 26.5%) and sinus
node dysfunction (n ¼ 23, 15.6%).
The mean BMI was 23.7±3.7kg/m2 and body surface area (BSA) was 1.60±0.18 m2. Our cohort
included patients with signiﬁcantly lower BMI
compared with IDE population (p < 0.0001). BMI
was not reported in the PAR, and BSA was not reported in both IDE and PAR.
Procedure composite efﬁcacy and safety outcomes
Of the 147 procedures attempted, 136 (92.5%)
reached the primary composite efﬁcacy and safety
outcomes.

Figure 1. Threshold, R-wave amplitude, impedance tested at implant
and follow-up. At each time point, mean values and standard deviations
are shown. N values are the numbers of patients for whom data were
available at each time point.

Procedure efﬁcacy outcomes
140 of the 147 implant procedures met the primary
efﬁcacy outcome (95.2%), deﬁned as achieving successful implant with threshold 2.0V at a pulse
width of 0.24msec at implant and follow-up, and
increase in threshold of 1.5V at a pulse width of

0.24msec during all clinical visits in the ﬁrst year
after implantation. Two implant attempts failed.
One failed implant was deployed 11 times without
ﬁnding a site with good parameters. The other failed
implant was in a patient with tortuous inferior vena
cava anatomy causing inability for the operator to
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Table 2. Description of all patients with pericardial effusion and possible periprocedural death.
Pericardial effusion

Indication for implant
Age
Sex
BMI (kg/m2)
BSA (m2)
CHF
COPD
eGFR (ml/min/1.73m2)
Perioperative
Antiplatelet
Anticoagulation
Treatment

Peri-procedural death

Patient A

Patient B

Patient C

Patient D

AF with bradycardia
79
F
22.6
1.47
N
N
71
N

AF with bradycardia
81
F
22.5
1.56
N
N
72
N

AF with bradycardia
87
F
22.8
1.52
Y
N
31
Aspirin

AF with bradycardia
85
F
20.5
1.36
N
N
54
N

N
Percutaneous drainage

N
Percutaneous drainage

N
Observation

N
N/A

AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; BSA ¼ body surface area; CHF ¼ congestive heart failure; COPD ¼ chronic obstructive
pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate.

torque the delivery catheter towards right ventricular septum. Both patients were subsequently
implanted with transvenous pacemakers uneventfully. Two patients had a high pacing threshold at
implantation (>2V/0.24 msec). Three patients had
increased threshold by more than 1.5V when tested
at follow-up visits. For successfully implanted cases,
the mean threshold tested at a pulse width of 0.24
msec was 0.61V at implant, 0.56V at 3 months and
0.63V at 1 year. The mean R-wave amplitude was
9.70mV at implant, 13.26mV at 3 months and
13.65mV at 1 year. (Figure 1)
Procedure safety outcome
Procedure safety outcome was reached in 143 out
of 147 patients (97.3%). The four patients who
developed major complications related to procedure
was described in Table 2. Three patients developed
pericardial effusion immediately after implantation,
two of which developed pericardial tamponade
necessitating urgent percutaneous pericardiocentesis and survived. One patient's pericardial effusion
was closely monitored and eventually did not
require drainage. There was one procedure related
death. The patient had atrial ﬁbrillation with pause
induced torsade de pointes. Temporary pacing wire
was inserted but procedure was complicated with
right groin hematoma. Hence the leadless pacemaker implantation was performed unconventionally via the left femoral vein. Patient developed
blood pressure drop and asystolic cardiac arrest two
hours after procedure. Echocardiogram during
resuscitation revealed no pericardial effusion. Groin
examination did not reveal signiﬁcant access site
hematoma. Retrospective review of telemetry reveals normal myocardial capture before arrest.
However, blood taking immediately before arrest

showed hemoglobin drop of 3g/dL compared to
before implantation. Possible cause of death was
thus perceived to be related to bleeding, such as
retroperitoneal hemorrhage. The patient was
referred for postmortem examination, but it was
waived by coroner.
There was no incidence of deep vein thrombosis,
pulmonary embolism, device dislodgement. There
was no incidence of arteriovenous ﬁstula or pseudoaneurysm. Two patients developed mild access
site infection, which was treated successfully with a
course of oral antibiotic and did not require hospitalization and hence were not adjudicated as major
complications.
Comparison of procedure efﬁcacy and safety
outcome with IDE study and PAR (Table 3)
The procedure efﬁcacy endpoint in IDE study was
deﬁned as a combination of a low (2 V at a pulse
width of 0.24 msec) and stable (increase of 1.5 V
from the time of implantation) pacing capture
threshold at the 6-month visit. [11] The PAR recorded electrical parameters but did not deﬁne an efﬁcacy endpoint [14]. Nevertheless the 1-year
threshold of PAR was reported. With this background, procedure efﬁcacy end-point was reached
in IDE in 292 (98.3%) out of 297 patients included for
analysis. The PAR included 566 patients for analysis
of threshold at 1 year, of which 546 (97.0%) had a
low threshold (<2V at a pulse width of 0.24 msec).
Allowing for this difference in timing of endpoint
measurement, our cohort had 130 patients’ pacing
threshold data available at three months and 129
(99.2%) had a low and stable threshold, using the
same efﬁcacy endpoint of IDE.
The procedure safety endpoint was the same for
IDE, PAR and CUHK cohort. It was deﬁned as

696/725 (96.0%)
13/725 (1.79%)
9 (1.24%)
7 (0.97%)
2 (0.28%)
4 (0.55%)
1/725 (0.14%)

Reaching safety outcome

Pericardial effusion
PE requiring intervention
Pericardiocentesis
Surgical repair
PE settled with observation
Possible death related to procedure

1776/1817 (97.7%) at
12 months
14/1817 (0.77%)
10 (0.55%)
8 (0.44%)
2 (0.11%)
4 (0.22%)
5/1817 (0.28%)

3/147 (2.0%)
2 (1.36%)
2 (1.36%)
0 (0%)
1 (0.68%)
1/147 (0.68%)

0.13
0.23

0.37

0.74
>0.99

0.31

0.58

N/A

N/A
0.64

0.64
N/A

P valueb
0.63
N/A

P valuea

12 months and ongoing

Retrospective, non-randomized
Nil
Successful implantation with
combination of a low (2 V/0.24 msec)
and stable (increase of 1.5 V/0.24 msec
from the time of implantation) threshold
at implantation and all visits during
the ﬁrst year.
same as IDE

CUHK

145/147 (98.6%)
140/147 (95.2%) (Successful implant
with low and stable threshold at implant
and all ﬁrst year visits)
129/130 (99.2%) (low and stable
threshold at 3-month visit)
143/147 (97.3%)

CUHK

24 months and ongoing

1801/1817 (99.1%)
549/566 (97%) low and stable
threshold at 1 year

PAR

same as IDE

Prospective non-randomized
Medtronics Inc.
Electrical parameters are collected at
implant and follow up, but there is no
standardization on follow up interval.

PAR

PE ¼ pericardial effusion, low and stable threshold means a threshold of 2 V/0.24 msec and increase of 1.5 V/0.24 msec from implantation.
IDE¼Investigational Device Exemption; PAR¼post-approval registry.
a
P value of comparisons between IDE and CUHK cohort.
b
P value of comparisons between PAR and CUHK cohort.

719/725 (99.2%)
292/297 (98.3%) low and
stable threshold at 6
months

Successful implant
Reaching efﬁcacy outcome

IDE

Freedom from system related or procedure related
major complications resulting in death, permanent loss
of device function as a result of mechanical or electrical
dysfunction, hospitalization, prolongation of
hospitalization by at least
48 hours, or system revision.
12 months and ongoing

Procedure safety outcome

Follow up period

Prospective non-randomized study
Medtronics Inc.
combination of a low (2 V/0.24 msec) and stable
(increase of 1.5 V/0.24 msec from the time of implantation)
pacing capture threshold at the 6-month visit.

Study design
Sponsorship
Efﬁcacy outcome

IDE

Table 3. a and b: Comparison of study design and outcomes with IDE study and PAR.

48
J HK COLL CARDIOL 2022;29(2):43e52

49

J HK COLL CARDIOL 2022;29(2):43e52

Table 4. Analysis of risk predictors for poor outcomes.
Risk factors

Composite efﬁcacy and
safety outcome reached (n ¼ 136)

Composite outcome not reached
(i.e. poor outcome)
(n ¼ 11)

P value

BMI (kg/m2)
BSA (m2)
Weight (kg)
Height (cm)
Age (year)
Sex ¼ Male
estimated GFR (ml/min/1.73m2)
Atrial arrhythmia
CHF
DM
COPD
Coronary artery disease
PVD
Stroke or TIA
HT
Prior pacemaker infection
Previously implanted with CIED

23.86 ± 3.79
1.61 ± 0.18
59.15 ± 11.33
157.6 ± 8.97
80.44 ± 8.91
70 (51%)
57.91 ± 22.82
74 (54%)
26 (19%)
46 (34%)
3 (2%)
23 (17%)
1 (0.7%)
20 (15%)
92 (68%)
7 (5%)
13 (10%)

22.12 ± 1.06
1.51 ± 0.11
53.18 ± 5.66
154.6 ± 7.41
81.90 ± 6.07
3 (27%)
58.11 ± 20.94
2 (18%)
5 (45%)
1 (9%)
0
0
0
4 (36%)
8 (73%)
1 (9%)
1 (9%)

0.001
0.099
0.007
0.292
0.594
0.209
0.977
0.114
0.054
0.175
>0.99
0.214
>0.99
0.082
>0.99
0.472
>0.99

BMI ¼ body mass index, BSA ¼ body surface area, GFR ¼ glomerular ﬁltration rate, CHF ¼ congestive heart failure, DM ¼ Diabetes
mellitus, COPD ¼ chronic obstructive pulmonary disease, PVD ¼ peripheral vascular disease, TIA ¼ transient ischemic attack,
HT ¼ hypertension, CIED ¼ cardiovascular implantable electronic device.

freedom from system-related or procedure-related
major complications resulting in death, permanent
loss of device function as a result of mechanical or
electrical dysfunction, hospitalization, prolongation
of hospitalization by at least 48 hours, or system
revision. 143 (97.3%) of CUHK cohort has reached
procedure safety outcome, which was comparable to
696 (96%) and 1776 (97.7%) in IDE and PAR
respectively (p ¼ 0.636 for comparison between
CUHK cohort and IDE, p ¼ 0.576 between CUHK
cohort and PAR). Pericardial effusion happened in 3
(2.0%) patients in CUHK cohort, 13 (1.79%) in IDE

Figure 2. Receiver operating characteristic (ROC) curve for predicting
poor composite efﬁcacy and safety outcome. The solid and dotted lines
representing prediction with BMI and body weight respectively. Area
under curve (AUC) for BMI was 0.683. AUC for body weight was 0.685.
BMI¼Body mass index.

and 14 (0.77%) in PAR. The rate of pericardial effusion tended to be higher in CUHK cohort but it did
not reach statistical signiﬁcance (p ¼ 0.74 between
CUHK cohort and IDE, p ¼ 0.13 between CUHK
cohort and PAR).
Procedure related death happened in 1 patient
(0.68%) in CUHK cohort, 1 in IDE (0.14%) and 5
(0.28%) in PAR and did not reach statistically signiﬁcant difference (p ¼ 0.31 between CUHK cohort
and IDE, p ¼ 0.37 between CUHK cohort and PAR)
Primary analysis on predictors of poor efﬁcacy and
safety outcome (Table 4)
Analysis was performed to compare the 11 patients with poor composite outcomes with 136 patients with favorable composite outcome. The BMI
of poor outcome group was signiﬁcantly lower
(22.12±1.06 vs 23.86±3.79 kg/m2, p ¼ 0.001). Low
body weight was also associated with poor outcome
(53.18±5.66 vs 59.15±11.33 kg, p ¼ 0.007), but low
body height was not. There was no statistically signiﬁcant between-group difference regarding to patients’ age, sex, body surface area, renal function,
prevalence of atrial arrhythmia, diabetes, chronic
obstructive airway disease, congenital heart disease,
coronary artery disease, congestive heart failure,
peripheral vascular disease, cerebrovascular events
or hypertension. Prior cardiac electronic device
implantation or its infection were both not associated with poor outcome.
With receiver operating characteristic (ROC) curve
analysis, BMI as a risk factor had an area under curve
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(AUC) of 0.683 for predicting poor outcome (95%
conﬁdence interval [CI]: 0.594e0.773), indicating a
fair predictor for poor composite outcome. Body
weight is found to have a similar AUC of 0.685 (95%
CI: 0.571e0.798), also suggesting fair predicting value
(Figure 2). With a median BMI of 23.76 as cutoff, the
sensitivity was 0.91, and speciﬁcity was 0.53.
Secondary analysis on effect of small body habitus
(Table 5)
To further investigate the effect of low BMI on implantation of Micra TPS, patients were stratiﬁed into
two groups using median BMI of the whole cohort
23.76kg/m2 as cut-off. Each group had 71 patients with
similar age and sex distribution. The mean BMI of the
two groups were 26.53 kg/m2 and 20.93 kg/m2
respectively. The mean BSA of two groups were
1.69m2 and 1.51m2 respectively. As found in the primary analysis, the low BMI group was associated with
poor composite outcome [10 (14%) vs 1 (1.4%),
p ¼ 0.009]. Low BMI group was more likely to have
mid or high septal device deployment (51% vs 17%,
p < 0.001), require more deployment attempts
(1.86 ± 1.97 vs 1.27 ± 0.97, p ¼ 0.026) and hence more
likely require device recapture (31% vs 17%, p ¼ 0.049)
and have a longer procedure time (46.0 ± 20.5 minutes
vs 37.7 ± 15.4 minutes, p ¼ 0.007).

Discussion
To our knowledge, this was the ﬁrst study dedicated to evaluate the effect of low body mass index
on implantation outcome of leadless pacemakers.
This study recruited patients with signiﬁcantly
lower BMI comparing with the IDE study. The main
ﬁndings of this study were summarized as follows:
1) Micra leadless pacemaker implantation in patients with low body mass index was associated with
an unfavorable composite efﬁcacy and safety outcomes. 2) Implantation in patients with low body
mass index was associated with a higher

implantation position, more deployment attempts
and longer procedure time.
Comparison of our cohort with IDE study and PAR
regarding efﬁcacy and safety outcomes
A previous study found that the risk factors
associated with cardiac injury included advanced
age, low BMI, female sex and COPD [17].
Comparing with the IDE study or PAR, our cohort
was arguably with higher risk proﬁle, with patients
of more advanced age, lower BMI and more women.
The incidence of COPD in our cohort was however
lower. Although with different risk proﬁle, the
safety outcome of our cohort was on par with the
IDE study and PAR. (97.3% reaching safety endpoint
for CUHK cohort, comparing to 96% for IDE study
and 97.7% for PAR). For efﬁcacy outcome, because
of a different follow-up schedule and timing of
outcome measurement, comparison between
studies should be interpreted cautiously. Our study
adopted a more stringent deﬁnition for efﬁcacy
outcome, namely successful implantation with
threshold being low (2.0V at a pulse width of
0.24msec at implant and during all follow-up in ﬁrst
year) and stable (increase in threshold of 1.5V at a
pulse width of 0.24msec during all clinical visits for
the ﬁrst year after implantation). This was in
contrast to the IDE trial which evaluated efﬁcacy
outcome only at 6-month visit. Allowing for this
difference, our cohort had an excellent threshold at
follow-up. (99.2% patients with stable and low
threshold at 3 months, comparing to 98.3% in IDE at
6 months and 97.0% in PAR at 1 year)
Implication of low body mass index during implant
procedure
From our primary analysis on potential risk factors affecting procedure composite outcomes, only
BMI and body weight showed signiﬁcant statistical
difference (p ¼ 0.001 and p ¼ 0.007 respectively).

Table 5. Secondary analysis of BMI affecting on implant position, need for device recapture and procedure time.
Age (year)
Male sex
Creatinine clearance (ml/min/1.73m2)
BMI (kg/m2)
BSA (m2)
Implant position at mid or high septum
Deployment attempts
Need for recapture
Procedure time (in minutes)
Poor composite outcome
Poor efﬁcacy outcome
Poor safety outcome
BMI ¼ Body mass index, BSA ¼ body surface area.

High BMI group (n ¼ 71)

Low BMI group (n ¼ 71)

P value

80.79 ± 9.38
41 (58%)
55.99 ± 21.63
26.53 ± 2.64
1.69 ± 0.16
12 (17%)
1.27 ± 0.97
12 (17%)
37.7 ± 15.4
1 (1.4%)
1 (1.4%)
0

80.29 ± 8.19
30 (42%)
59.63 ± 23.11
20.93 ± 2.11
1.51 ± 0.15
35 (51%)
1.86 ± 1.97
22 (31%)
46.0 ± 20.5
10 (14%)
6 (8.5%)
4 (5.6%)

0.731
0.065
0.334
<0.001
<0.001
<0.001
0.026
0.049
0.007
0.009
0.116
0.120
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While our cohort may not have the statistical power
to pick up other risk factors with less signiﬁcant
contribution to procedure outcomes, it is reasonable
to assume procedure outcomes is related to multiple
patient-related and procedure-related factors. The
AUC for ROC curve was 0.683 for BMI. It indicates if
only BMI is considered, it has fair predicting value.
With the median BMI 23.76 kg/m2 adopted as cutoff,
the sensitivity is 0.91, and speciﬁcity is 0.53. This
indicates the median BMI of our cohort is an
excellent cutoff to screen for patients with potentially poor outcomes.
The apex has the characteristic of being heavily
trabeculated [22] hence potentially being a more
secure position for deployment with less dislodgement rate. However, as dislodgement is rare for
Micra leadless pacemaker (0 for IDE trial, 0.11% for
PAR), preference of deploying the Micra TPS in
non-apical position was being adopted by some
implanters [23]. A recent prospective study conducted in Hong Kong suggests that mid-septum
implantation approach is safe even for patients with
high risk proﬁle [24]. While we did not have a
standardized protocol for implant site selection for
the CUHK cohort, the observed higher implantation
position associated with smaller body mass index
may be due to the difﬁculty for the delivery catheter
to reach the apex for small right ventricles because
of unfavorable angulation. There was also a report
on difﬁcult device recapture in apically deployed
device in patient with small body build [16]. Further
research is required to conclude the best empirical
implant position to aim at for ﬁrst deployment.
Recapture of device is required if electrical parameters are unsatisfactory, or if pull and hold test
failed. The options for deployment location may be
limited given the constraint on maneuverability,
which might lead to suboptimal electrical parameters despite repositioning. Also, with smaller heart
and unfavorable anatomy, the operator may be less
conﬁdent to make an adequate “goose neck” before
deploying the device. This can lead to suboptimal
contact between the device cathode and the
myocardium, and translate into unsatisfactory
parameters.
The need for multiple device deployment and
hence need to recapture device results in a longer
procedure time. Other possible contributory factors
for longer procedure time include difﬁculty in
establishing venous access and negotiating the
large-bore delivery catheter in patients’ venous
system and right heart. Also, operators may tend to
be more cautious when dealing with patients of
smaller body build.
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Study limitations
Firstly, this was a retrospective study and hence
was subjected to bias associated with missing data.
Although all patients’ implantation records and
ﬂuoroscopic images were available, BMI information was only available in 142 (96.6%) patients.
Nonetheless, the strength of the retrospective
design is the avoidance of selection bias, since
consecutive implantation was studied.
Secondly, with the retrospective study design,
there was no standardized protocol for implantation
procedure. Hence, the ﬁnding of low BMI patients
being more likely to receive a mid or high septal
implant should be interpreted with caution. The
different operators’ experience and preference may
also affect the ﬁnal implant position.
Thirdly, because this was a single-center study,
the sample size was smaller than multicenter trial
and registry. With the small event rate, multivariate
analysis to identify independent risk factors for
poor composite endpoint could not be reliably
performed. Yet despite the small event rate, the
p value for BMI difference between patients with
and without poor outcome is 0.001, a difference
unlikely to be accountable by chance.
Last but not least, although our study suggested
low BMI was associated with less satisfactory
outcome for leadless pacemaker implantation,
whether transvenous pacemaker would yield better
outcome in this group of patients was not known.

Conclusion
Micra leadless pacemaker implantation in patients with low body mass index was associated with
an unfavorable composite efﬁcacy and safety
outcome. Implantation in patients with low body
mass index was associated with a higher implantation position, more device recapture and longer
procedure time.
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